|Articles|July 24, 2014

Incomplete HPV Vaccination May Offer Some Protection

Minority women who received the human papillomavirus (HPV) vaccine  even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated. These findings appear in the journal Sexually Transmitted Diseases.

Researchers from Boston University School of Public Health and School of Medicine conducted a cross-sectional study of 235 women age 21 to 30 undergoing routine cervical cytology testing. HPV status and demographic and behavioral characteristics were self-reported and verified with electronic medical records.

"Although data clearly indicate better immune responses and vaccine efficacy against both genital warts and cervical dysplasia when vaccination occurs before age 14, this study suggests that HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut," explains co-author Rebecca Perkins, MD, MSc, assistant professor of Obstetrics and Gynecology at Boston University School of Medicine and a gynecologist at Boston Medical Center.

At the time of the study, 41 percent had received at least one HPV vaccination; 97 percent of women were vaccinated after sexual debut. Ten percent of women had an abnormal cervical cytology result. The prevalence of abnormal cytology was 65 percent lower in women who received at least one HPV vaccination as compared to unvaccinated women.

According to the researchers continued surveillance of HPV vaccination is necessary to identify clinical benefits, particularly given the low rate of vaccine uptake and completion and vaccination of many young women after sexual debut.

"Studies should continue to compare vaccine effectiveness before and after sexual debut and by vaccine doses received and to explore the role of herd immunity," adds Perkins.

Funding for this study was provided by the American Cancer Society.


Related to this article

Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.